Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Barclays upgraded CytomX Therapeutics to "strong-buy" in its latest analyst report.
  • Oppenheimer initiated coverage with an "outperform" rating and USD 7.00 price target.
  • Average analyst rating is "Buy" with consensus price target of USD 5.30.

CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.

In a separate development, Oppenheimer began coverage of CytomX Therapeutics on Thursday, July 31, assigning an "outperform" rating and setting a price target of USD 7.00 per share.

Overall, CytomX Therapeutics carries an average rating of "Buy," with a consensus price target of USD 5.30. The range of targets indicates differing views on the company’s potential share price performance in the near to medium term. Analyst ratings and price targets are subject to change depending on market conditions, clinical developments, and company-specific announcements.

CytomX Therapeutics specializes in oncology research and development, with a focus on conditionally activated biologics designed to act within the tumor microenvironment. Its platform technology seeks to validate targets for antibody-drug conjugates (ADCs), expand therapeutic windows for novel T-cell engagers (TCEs) aimed at solid tumors, and improve therapeutic indices for immune modulators such as cytokines. Beyond oncology, the company is also applying its PROBODY technology to preclinical research across other therapeutic areas.